Detection of metallothionein and alpha-methylacyl CoA racemase as potential new markers for prostate carcinoma

Investor logo

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

MASAŘÍK Michal GUMULEC Jaromír KUCHTÍČKOVÁ Šárka ADAM Vojtěch KŘÍŽKOVÁ Soňa KIZEK René

Year of publication 2009
Type Article in Periodical
Magazine / Source International Journal of Molecular Medicine
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords prostate carcinoma; tumor markers; metallothionein; AMACR
Description In many developed countries, prostate cancer is the second leading cause of cancer-related deaths among men. Therefore, having reliable and easy-to-detect marker is needed to treat this disease successfully. Metallothioneins (MT) are a group of proteins rich in cysteine with molecular weights ranging from 6 to 10 kDa. Their main physiological functions are homeostatic control and detoxification of the metals. The role of MT in tumour tissue remains still unclear, but MT can be considered as new promising tumour marker. Besides MT, alpha-methylacyl CoA racemase AMACR has been proven to be one of the few biomarkers that can help distinguish cancer from benign cells, with high sensitivity and specificity for prostate carcinoma. In this study we proposed new methodical approaches in MT and AMACR detection in cell line model and then reciprocal correlation of obtained data. The LNCaP cell line used in our experiments was isolated in 1977 by J.S. Horoszewicz, et al. An adsorptive transfer stripping technique coupled with differential pulsed voltammetry Brdicka reaction was employed for the determination of metallothionein MT and AMACR level in cell lines extract. MT content was hundred of ug per g of soluble proteins and was higher as well as for AMACR compared to non-tumour cell line.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info